Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Receivables - Other: 2023-2024

Historic Receivables - Other for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Dec 2024 value amounting to $1.7 million.

  • NewAmsterdam Pharma Co N.V's Receivables - Other rose 136.88% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 136.88%. This contributed to the annual value of $1.7 million for FY2024, which is 99.77% up from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Expense - Property Taxes and Insurance of -$8 as of FY2022.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Receivables - Other ranged from a high of $1.7 million in FY2024 and a low of $875,000 during FY2023.
  • Its 1-year average for Expense - Property Taxes and Insurance is -$8, with a median of -$8 in 2022.
  • Data for NewAmsterdam Pharma Co N.V's Receivables - Other shows a peak YoY skyrocketed of 99.77% (in 2024) over the last 5 years.
  • Over the past 2 years, NewAmsterdam Pharma Co N.V's Receivables - Other (Yearly) stood at $875,000 in 2023, then spiked by 99.77% to $1.7 million in 2024.